## **COPY FOR IB**

10/53901 1 pct/kr2003/001889

## PATENT COOPERATION TREATY

# **PCT**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

REC'D	1	3	MAY	2005
WIPO	_			PCT

(PCT Artcle 36 and Rule 70)

Applicant's or agent's file reference PCT-031226	FOR FURTHER ACTION		nofTransmittalofInterna Report (Form PCT/IPEA	
International application No. PCT/KR2003/001889	International filing date(day/mo		Priority date (day/mont) 26 DECEMBER 2002	
International Patent Classification (IPC)  IPC7 C07J 17/00		`		
Applicant  AMOREPACIFIC CORPORA	TION et al			·
amended and are the basis for 70.16 and Section 607 of the These annexes consist of a total of These annexes consist of the total of These annexes consist of th	according to Article 36.  of3sheets, including the ANNEXES, i.e., sheets for this report and/or sheets core Administrative Instructions untilsheets.  clating to the following items:  of opinion with regard to novelty ention  under Article 35(2) with regard ations supporting such statements.	ding this cover sh of the description taining rectification der the PCT).	eet.  n, claims and/or drawing ons made before this A	s which have been uthority (see Rule
Date of submission of the demamd	Date	of completion of	this report	
02 APRIL 2004 (02	2.04.2004)	26 APRIL 20	05 (26.04.2005)	
Name and mailing address of the IPEA/I Korean Intellectual Property 920 Dunsan-dong, Seo-gu, Republic of Korea Facsimile No. 82-42-472-7140	y Office Daejeon 302-701,	phone No. 82-42		486



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International aplication No.

PCT/KR2003/001889

I.	Basis	s of the report
1.	With	regard to the elements of the international application:*
	$\boxtimes$	the international application as originally filed
		the description:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of
		the claims:
		pages, as originally filed pages, as amended (together with any statment) under Article 19
		pages, filed with the demand
		pages, filed with the letter of
		the drawings:
		pages, as originally filed
		pages, filed with the demand
		pages, filed with the letter of the sequence listing part of the description:
	ш	pages, as originally filed
٠.		pages filed with the demand
•		pages, filed with the letter of
2. ∵∴	the i	regard to the language, all the elements marked above were available or furnished to this Authority in the language in which international application was filed, unless otherwise indicated under this item.  se elements were available or furnished to this Authority in the following language English which is the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)).  the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/
3.	Wit	or 55.3).  the regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international liminary examination was carried out on the basis of the sequence listing:
	$\boxtimes$	contained inthe international application in written form.
	$\boxtimes$	filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
		furnished subsequently to this Authority in computer readable form
		The statement that the subsequently furnished written sequence listing does not go beyond the disc losure in the international applicationas as filed has been furinshed.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.	Ш	The amendments have resulted in the cancellation of:
		the description, pages
		the claims, Nos.
		the drawings, sheets
5.		
		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2(c)).**
*	Repla in this and 7	scement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to s opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 [0.17].
**	Any r	replacement sheet containing such amendments must be referred to under item I and annexed to this report.



International aplication No.

PCT/KR2003/001889

V. Reasoned statement under Article 35(2) with regard to no	velty, inventive sten or industrial applicability.
citations and explanations supporting such statement	y and the state of the desiral applicability,

1.	Statement			
	Novelty (N)	Claims Claims	1-3 4	YES NO
	Inventive step (IS)	Claims Claims	1-3	YES NO
ı	Industrial applicability (IA)	Claims Claims	1-4	YES NO

## 2. Citations and explanations (Rule 70.7)

This present invention relates to a promoter containing ginsenoside compound K (20-0-b-D-glucopyranosyl-20(S)-protopanaxadiol) to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of hyaluronic acid, and an anti-aging agent containing the promoter for the production of hyaluronic acid as an effective ingredient.

The following documents have been considered for the purpose of this report:

D1: KR 2003-65273 A (II Hwa Co., Ltd.) 06 Aug. 2003

D2: KR 2003-80429 A (Pacific Corporation) 17 Oct. 2003

D3: KR 2003-60017 A (Pacific Corporation) 12 Jul. 2003

D4: KR 2003-60018 A (Pacific Corporation) 12 Jul. 2003

#### 1. Novelty

Claim 4 relates to an anti-aging agent containing the promoter for the production of hyaluronic acid. However, the subject-matter of claim 4 does not appear to be novel, because documents D1-D4 disclose the same anti-aging agent containing ginsenoside compound K (20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol). Therefore, the subject-matter of claim 4 is not considered to be novel under PCT Article 33(2).

#### 2. Inventive Step

The prior art does not teach or suggest the use of a promoter containing ginsenoside compound K or an anti-osteoarthritis agent containing the promoter. Therefore, the subject-matter of claims 1-3 is considered to involve an inventive step under PCT Article 33(3).

#### 3. Industrial Applicability

The subject-matter of claims 1-4 is considered to be industrially applicable under PCT Article 33(4).